tbuckley/cabot-search huggingface dataset:
Abstract P256: Stability of Obesity and Metabolic Health and the Risk of Cardiovascular Disease
Authors: Todd Sponholtz, Justin B Echouffo-Tcheugui, Ramachandran S Vasan
Journal: Circulation (2018)

Introduction: Metabolic syndrome (MetSyn) reportedly confers higher risk of cardiovascular disease (CVD) than its individual components. Although typically defined as a binary exposure, each of its component factors can vary over time. Little is known about whether CVD risk differs according to MetSyn stability. Methods: We defined longitudinal states of obesity and metabolic health among 2,952 Framingham Offspring Study participants for whom we had sufficient data to define MetSyn at ≥4 exams between Exams 2 (1979-1983) and 9 (2011-2014). Obesity was defined as BMI ≥30 kg/m 2 , high triglycerides as ≥150 mg/dL/taking lipid-lowering medication, low HDL as &lt;40 mg/dL for males/ &lt;50 mg/dL for females; high blood pressure as systolic blood pressure ≥130 mm Hg/diastolic blood pressure ≥85 mm Hg/taking antihypertensive medication, and high blood glucose as ≥100 mg/dL/taking antidiabetic medication. Metabolic health was defined as having &lt;2 metabolic conditions. Obesity and metabolic health were classified as unstable if there was a change from one state to the other in ≥33% of observations occurring before a CVD event or end of follow-up, stable obese/metabolically unhealthy if not unstable and &gt;50% of observations were classified as stable obese/metabolically unhealthy, or stable non-obese/metabolically healthy otherwise. CVD was defined as any of the following coronary death, myocardial infarction, coronary insufficiency, angina pectoris, stroke, transient ischemic attack, intermittent claudication, or congestive heart failure. We estimated hazard ratios (HRs) and 95% confidence intervals (95% CIs) using Cox proportional hazards regression with age as the time scale. Results: We classified 332 participants (11.3%) as having unstable metabolic health, and 130 (4.4%) as having unstable obesity. We observed 1,206 events in 75,673 person-years of follow-up (median 30 years). Participants classified as stable metabolically unhealthy had the highest CVD risk (HR 1.77, 95% CI 1.47, 2.13, compared to stable metabolically healthy). Stable obesity was associated with a 48% (95% CI 24, 80) increase in CVD risk relative to stable non-obese. Unstable metabolic health and obesity were associated with moderate increases in risk compared to stable metabolically healthy and stable non-obese (HRs: 1.32, 95% CI 1.03, 1.71 and 1.25, 95% CI 0.88, 1.77, respectively). There was no interaction between obesity- and metabolic health stability (p interaction =0.23). Conclusions: In our sample, stability of obesity and of metabolic health influenced CVD risk, with the highest risk of CVD observed among stable metabolically unhealthy participants. Instability of both obesity and metabolic health convey a risk intermediate between the stable obese/metabolically healthy and stable non-obese/metabolically unhealthy conditions.
Artificial Intelligence Guided Precision Medicine Approach to Hematological Disease
Authors: Tomomi Takei, Kazuaki Yokoyama, Nozomi Yusa, Sousuke Nakamura, Miho Ogawa, Kanya Kondoh, Masayuki Kobayashi, Asako Kobayashi, Mika Ito, Eigo Shimizu, Mako Yamamoto, Rika Kasajima, Koichiro Yuji, Rui Yamaguchi, Yoichi Furukawa, Seiya Imoto, Satoru Miyano, Arinobu Tojo
Journal: Blood (2018)
AB0504 Efficacy of prolonged maintenance monotherapy with rituximab in patients with primary sjÖgren’s syndrome: three-year follow-up
Authors: A. Torgashina, E. Rodionova, T. Safonova, V. Vasiliev
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> There are currently no effective systemic therapies of primary Sjögren's syndrome (pSS); however, open label series have suggested that rituximab may be beneficial for systemic and glandular manifestations. <h3>Objectives</h3> To estimate clinical efficacy and safety of prolonged maintenance B-cell targeted monotherapy for pSS. <h3>Methods</h3> 25 with pSS ACR-EULAR criteria, 2016 were included in this research. Indications for treatment were significant immunological activity (high titres of rheumatoid factor (RF) and anti-nuclear antibodies) and/or hypergammaglobulinemia in 20 patients, parotid enlargement (lymphoma was excluded) – 5, arthritis – 3, lymphadenopathy – 3, severe keratoconjunctivitis sicca in 7, of them corneal ulceration – 3, leukopenia – 4 patients. Patients were treated initially with 2 infusions of rituximab (1000 mg) given once every two weeks with premedication (methylprednisolone (250 mg) and chloropyramine). Then all patients received maintenance therapy with rituximab 500 mg every 6 months. Duration of treatment and follow-up was at least 3 years. Median follow-up was 45 months (36–90). Patients were evaluated, using immunologic, subjective parameters, salivary/lacrimal function at baseline and in 24 weeks and then every year during the follow-up. Patients were not concomitantly treated with another immunosuppressant agent or glucocorticoids daily. <h3>Results</h3> All patients were women with a mean age at diagnosis of 49 years [29–70] and median duration of disease was 6 years (1–20). The average cumulative dose of rituximab was 10000 mg (7000–12000 mg). The median European Sjögren's Syndrome disease activity index (ESSDAI) decreased from 2.5 (2–3) to 0 (0–1) (p=0.01) by the end of the study. The increase in salivation and lacrimation according to Schirmer test and tear film break-up time was insufficient, however, in all patients the size of the salivary glands normalised and the recurrent parotitis stopped. Furthermore, 7 patients with severe keratoconjunctivitis sicca improved the course of the disease. The healing of corneal ulceration in all patients was observed one year after the initiation of therapy. A significant decrease in the RF level (from 198 IU/ml (51–442) to 71 IU/ml,<sup>30–73</sup> p=0,002) and gammaglobulins (from 28%±5% to 19,3%±3,5%, p=0,001) was observed one year after this study beginning. Unreliable decrease of immunoglobulins was noted in 23% of patients by the end of the follow-up, that did not increase the risk of secondary infections. We observed good tolerability of therapy, only 4 patients had mild infusion reactions. <h3>Conclusions</h3> Rituximab therapy is highly effective, well tolerated and helps to avoid long-term use of glucocorticoids/cytotoxic agents in pSS. <h3>Disclosure of Interest</h3> None declared
Does Mixed Chimerism after Allogeneic Hematopoietic Cell Transplantation in Patients with Fanconi Anemia Impact on Outcome?
Authors: Mouhab Ayas, Khawar Siddiqui, Antonette Amao, Abdullah Aljefri, Ali Abdallah Ahmari, Ibrahim A. Ghemlas, Hawazen S. Alsaedi, Awatif Alanazi, Amal Al-Seraihy
Journal: Blood (2018)
THU0138 Occurrence of in-stent restenosis after coronary drug-eluting stent implantation in patients with rheumatoid arthritis
Authors: O.C. Kwon, W.J. Seo, J.S. Oh, S. Hong, C.-K. Lee, B. Yoo, Y.-G. Kim
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Rheumatoid arthritis (RA) is associated with increased risk of cardiovascular events. Thus, patients with RA have a greater chance of undergoing coronary drug-eluting stent (DES) implantation. However, it is not known whether the rate of in-stent restenosis (ISR) is also increased in RA patients. <h3>Objectives</h3> To investigate characteristics of in-stent restenosis (ISR) after drug-eluting stent (DES) implantation in patients with rheumatoid arthritis (RA), and to evaluate the effect of disease modifying anti-rheumatic drugs (DMARDs) on ISR. <h3>Methods</h3> Patients with RA who underwent DES implantation between January, 2005 and March, 2017 were included. Characteristics of the patients and the vessel lesions were reviewed retrospectively. To evaluate the effect of DMARDs on ISR, previously known ISR risk factors and ISR incidence were compared between the treated vessels of patients who did and did not receive specific DMARDs. <h3>Results</h3> In total, 30 RA patients (43 vessel lesions) were included. 4 treated vessel lesions developed ISR (4/43, 9.3%) in median 106.8 (81.1–109.0) months after DES implantation. Compared with the previous data in general population (occurrence of ISR: 3%–20%, mean time of ISR occurrence: 13 months), the incidence was similar, but the time to ISR occurrence was much longer. In the comparison of patients receiving MTX (n=31 vessel lesions) and those not receiving MTX (n=12 vessel lesions), the ISR incidence was significantly different [0/31 (0.0%) vs. 4/12 (33.3%), p=0.004]. <h3>Conclusions</h3> ISR after DES implantation in RA patients occurs in a similar rate, but after a much longer period of time than in the general population. Administration of MTX in patients with RA might have potential benefit to prevent ISR after DES implantation. <h3>Acknowledgements</h3> None. <h3>Disclosure of Interest</h3> None declared
AB0412 Dynamics of quantitative body composition indices by the method of dual-energy x-ray absorptiometry (DRA) in patients with early ra depending on the achieved activity of the disease
Authors: Y. Gorbunova, T. Popkova, L. Kondratyeva, A. Smirnov, E. Nasonov
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Adipose tissue an active endocrine organ. In pts with RA the redistribution of body fat mass. Using BMI and WC do not allow to distinguish between fat and lean (muscle) mass. Performing dual-energy X-ray absorptiometry allows to specify the quantitative composition of the body(mass of adipose tissue and muscle) in pts with early RA. <h3>Objectives</h3> to compare the indicators of the quantitative composition of the body in groups of RApts with different disease activity before and after the appointment of therapy. <h3>Methods</h3> included 37pts with early RA(ACR/EULAR2010), 57 [46.5, 62] yrs, duration of disease 6 [5.5,15.5]mths, IgMRF seropositive antiCCP, with high RA activity(DAS285.5 [5.1,6], SDAI 32.4 [22.4, 42], CDAI 29 [19.7, 39.5]). After inclusion in the study, all pts started receiving MTX 10 [10–15 mg/week), after 12 weeks, with ineffective MTX, ADA 40 mg/<sup>2</sup> weeks was prescribed. The quantitative composition of the body was determined initially and after 6mths by means of DXA using the apparatus HOLOGIC,analysing the following parameters:the total, of fat and lean mass. <h3>Results</h3> By the 24th week of therapy, 13 (35%)pts with earlyRA received combined therapy(ADA, MTX), 24 (65%) pts with RA monotherapy MTX. Depending on the activity of RA(DAS28)by the 24th week of therapy, pts are divided into 2groups: I(n=18) pts with remission/low activity, II(n=19)with moderate/high RA activity (table 1). Initially, the groups differed in fat mass:this index was higher in the group of pts with moderate/high activity persisting, compared with the group of pts with remission/low activity of RA:30.2 kg versus 19.4 kg. In the I group of pts before the treatment and after 6mths of therapy,a statistically significant decrease in muscle mass was observed:from 45.2 kg to 41.6 kg. A decrease in the mass of adipose tissue after 24 weeks of therapy was noted in the IIgroup of pts with RA:from 30.2 kg to 28.2 kg. The difference in the indices between the groups by the 6 month of therapy was noted for the mass of adipose tissue. This composition of the body score was also higher in pts with moderate and high RA activity, compared to the group of pts with remission/low RA activity: 28.2 kg versus 18.9 kg(p&lt;0.05 in all cases). <h3>Conclusions</h3> pts with RA who achieved Igroup after 6 mths of therapy initially had a smaller volume of adipose tissue, compared with pts with moderate and high RA activity. Despite the achievement of remission after 6mths of therapy,a loss of lean mass(probably the development of rheumatoid cachexia) continued in some pts, but these data need confirmation in studies with a large number of pts and a longer period of follow-up. <h3>Disclosure of Interest</h3> None declared
THU0206 Add-on short-course tocilizumab accelerates dose tapering of glucocorticoids in rheumatoid arthritis: results from a chinese prospective cohort study
Authors: J.-W. Wang, Y.-Q. Mo, X.-Y. Wang, L.-F. Chen, J.-D. Ma, J.-Z. Lin, D.-H. Zheng, L. Dai
Journal: Annals of the Rheumatic Diseases (2018)

Background  In real-world clinical practice, self-paid and expensive price limit the application of bDMARDs and only a few patients especially in developing countries could afford long-term use. Only 9.1%>11% of Chinese rheumatoid arthritis (RA) patients were treated with bDMARDs with mean course no more than 6 months. Such short course of bDMARDs had always been raised doubt about their efficacy and benefit for rare reported evidence.  Objectives  To explore the efficacy of additional short-course of Tocilizumab (TCZ) combined with csDMARDs in real-world RA management.  Methods  Consecutive patients with active RA (DAS28-ESR>2.6) who had completed 6 month follow-up were retrospectively recruited from a prospective RA cohort (n=582). All patients were treated according to the treat-to-target strategy and patient’s willingness especially biologics use. RA patients who finished at least 3 infusions of TCZ (8 mg/Kg/4 weeks) were included as add-on TCZ group, and matched RA patients without any bDMARDs by age, sex and disease activity at baseline with the ratio of 1:1 were included as csDMARDs group. Clinical data were collected according to the 2017 EULAR recommendation at baseline and regular visits at week 4, 12 and 24.  Results  (1) The baseline characteristics of 101 paired RA patients showed no significant difference except for lower csDMARDs-naive percentage between two groups (table 1). (2) During 24 week follow up, there were significantly higher percentage of patients in add-on TCZ group achieving therapeutic target (DAS28-ESR  Conclusions  Add-on short-course TCZ may be an alternative induction strategy for RA patients in developing countries which can quickly achieve target and accelerate dose tapering of GC.  Acknowledgements  This work was supported by National Natural Science Foundation of China (grant no. 81471597, 81671612 and 8160147) and Guangdong Natural Science Foundation (grant no. 2016A030313307 and 2017A030313576).  Disclosure of Interest  None declared
Right Ventricular–Pulmonary Artery Coupling—Let’s Not Lose the Forest for the Trees
Authors: Muddassir Mehmood
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Abstract 10726: Long-term Outcomes of Bradycardia in Adults Free of Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis (MESA)
Authors: Ajay Dharod, Elsayed Z Soliman, Farrah Dawood, Haiying Chen, Steven Shea, Saman Nazarian, Alain G Bertoni
Journal: Circulation (2013)

Introduction: Asymptomatic sinus bradycardia (heart rate (HR) <60 beats per minute (BPM)) has been associated with lower cardiovascular (CVD) risk. Information is sparse, however, regarding HR <50 ...
Abstract 17446: Fasting Remnant Cholesterol Levels Predict Incident Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease: The ACCELERATE Trial
Authors: Giacomo Ruotolo, Michael A Lincoff, Venu Menon, Ellen McErlean, Kathy Wolski, Govinda Weerakkody, Jeffrey S Riesmeyer, Steven E Nissen, Stephen J Nicholls
Journal: Circulation (2017)

Background: Statins reduce LDL-C and cardiovascular risk in patients with atherosclerotic cardiovascular disease (ASCVD). However, in patients treated with statins, it is uncertain whether measures...
Genetic Characterization of ABT-199 Sensitivity in Human AML
Authors: Marie-Eve Bordeleau, Richard Bisaillon, Clarisse Thiollier, Jana Krosl, Bernhard Lehnertz, Vincent-Philippe Lavallee, Tara MacRae, Labelle Caroline, Geneviève Boucher, Isabel Boivin, Giovanni D'Angelo, Sylvie Lavallée, Anne Marinier, Sébastien Lemieux, Josée Hébert, Guy Sauvageau
Journal: Blood (2018)
SAT0676 Ultrasound detected inflammation in rheumatoid arthritis: elucidating the relationship with clinical manifestations at the wrist
Authors: Y.K. Tan, R.B. Moorakonda, J.C. Allen, P.G. Conaghan, L.C. Chew, J. Thumboo
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Tender and swollen joint counts are part of rheumatoid arthritis (RA) disease activity assessments. While subclinical synovitis is now a well-known entity, the relationship between tender and swollen joints and ultrasound (US) detected inflammation has not been well explored. <h3>Objectives</h3> To compare US detected inflammation (synovitis and/or tenosynovitis) with joint swelling and/or tenderness of the wrist, an important joint in RA. Tendons are included as tenosynovitis on US can be mistaken for joint involvement clinically. <h3>Methods</h3> Wrist outcome groups (Groups) 1–4 were identified: 1=S0 T0 (not swollen, not tender); 2=S0 T1 (not swollen but tender; 3=S1 T0 (swollen but not tender); 4=S1 T1 (swollen and tender). Power Doppler (PD) and grey-scale (GS) US were used to grade (a) synovitis semi-quantitatively (0–3) at the following joint recesses: dorsal radiocarpal and intercarpal, dorsal ulnocarpal and volar radiocarpal, and (b) tenosynovitis dichotomously (0=no, 1=yes) at the following tendon sites: extensor digitorum, extensor carpi ulnaris, and flexor digitorum. Scores on each wrist consisted of a PD score, a GS score and a combined (PD +GS) US (CUS) score. Positivity (+ve) for PD, GS and CUS scores was analysed using a generalised linear repeated measures mixed model with binary distribution and logit link. Scores were analysed using a general linear repeated measures mixed model assuming Gaussian errors. In both analyses, patients were modelled as random effects, and wrist (R/L) and follow up visit (baseline, 3 months) as fixed effects. Pairwise comparisons on +ve and scores were carried out among the 4 groups in the context of the models. P-values were not adjusted for multiple comparisons. <h3>Results</h3> 122 wrist assessments resulted from 32 RA subjects (87.5% female; 78.1% Chinese; mean (SD) disease duration of 42.8 (52.9) months) who either started or escalated on systemic corticosteroids and DMARDs. All subjects were assessed at baseline and 29 at 3 months. Significant differences among Group scores were: 4 vs 1 (PD, p=0.0031; GS, p=0.0159; CUS, p=0.0045), 4 vs 2 (PD, p=0.0176; GS, p=0.0160; CUS, p=0.0074), and 4 vs 3 (CUS, p=0.0374). Significant differences among +ve were: 4 vs 1 (PD, p=0007), 4 vs 2 (PD, p=0.0234), and 3 vs 1 (PD, p=0.0202). No significant Group differences were found for 2 vs 1 (for +ve and scores) and when comparing the 4 groups for GS +ve and CUS +ve. Table 2 shows the frequency distribution of patients by wrist and follow up. There were no significant effects attributable to differences in wrists or follow up visit (p-values all &gt;0.05). <h3>Disclosure of Interest</h3> None declared
AB0454 Biological therapies survival in adults and juvenile onset arthritis. data from biobadaguay registry
Authors: M.G. Avila-Pedretti, Z. Morel, N. Cabrera, S. Cabrera-Villalba, I. Acosta Colman, P. Babak, P. Melgarejo, G. Elizaur, M. Franco, P. Delgadillo, D. Cordovilla Montero, J. Losanto, L. Roman, E. Paredes, J. Mazzoleni, P. de Abreu
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Survival of biological therapies (BT) may be considered as an indicator of efficacy and safety of the drug. BT survival have been studied mainly in adult’s patients, whereas only few studies have been focused on paediatric population to date. <h3>Objectives</h3> To analyse and compare BT survival in adults and juvenile onset arthritis patients from BIOBADAGUAY registry. <h3>Methods</h3> Patients with a chronic inflammatory arthritis enrolled in the Paraguayan-Uruguayan biological register (BIOBADAGUAY) between2015 and 2017 where included. For this study, patients were divided in two groups: 1. Adults with anychronic inflammatory arthritis and 2. Patients with juvenile idiopathic arthritis (JIA). To compare the groups according to BT, only the first biotherapy was considered. Survival analysis was performed using Kaplan-Meier estimators and proportional hazard regression model. First we analysed global BT survival in both groups; secondly we compare BT survival between groups. <h3>Results</h3> From 778 BTs(etanercept n=184, adalimumab n=440, rituximab n=44, infliximab n=27, tocilizumab n=75, and others n=8), 556 where identify as first line BTs. Of these, only adalimumab and etanercept were included in the study due to sufficient number prescriptions in both groups for the analysis. We found a mean survival times for adults of 289 (±20.7 SD) weeks for etanercept and 287 (±8.6 SD) weeks for adalimumab. In JIA patients the mean survival were 243 (±26.0 SD) and 216 (±24.0 SD) weeks for etanercept and adalimumab respectively When comparing survival between groups, we found that JIA presented more discontinuation of BT when compare with adult patients (p=4.4 × 10–4, HR=0.51 [95%CI, 0.35–0.73]). Similar results were observed when analysing only etanercept (p=3.92 × 10–2; HR=0.50 [95% CI, 0.26–0.97]) or adalimumab (p=1.20 × 10–3; HR=0.48 [95% CI, 0.30–0.75])treatments. Then we analysed withdrawn motive in JIA patients, and found that remission was the principal reason of discontinuation in this group of patients. Finally, we stratified survival analysis by discontinuation according to adverse events, and found that JIA group presented a lower risk of discontinuation due to adverse events than adults (p=1.96 × 10–1; HR=2.18 [95% CI, 0.67–7.07]). <h3>Conclusions</h3> In our study we have analysed mean BT survival between adults and JIA at the BIOBADAGUAY registry. When we compared both groups of patients it was observed that JIA patients presented more BT discontinuation but due to remission. <h3>Disclosure of Interest</h3> None declared
The Role of microRNAs in the Pathogenesis of Erdheim-Chester Disease and Their Potential Use As Biomarkers for Diagnosis and Prognosis of the Disease
Authors: Ran Weissman, Nir Pilar, Benjamin H Durham, Michelle Ki, Roei D Mazor, Omar I Abdel-Wahab, Noam Shomron, Ofer Shpilberg, Eli L Diamond, Oshrat Rokah
Journal: Blood (2018)
Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia
Authors: Kerry A. Rogers, Ying Huang, Amy S. Ruppert, Farrukh T. Awan, Corrinne Hoffman, Kami J. Maddocks, Mark Reid, Jennifer A. Woyach, Thomas Whitlow, Jeffrey A. Jones, John C. Byrd
Journal: Blood (2018)
Efficacy and Safety of Carfilzomib and Dexamethasone in Lenalidomide Exposed and Refractory Multiple Myeloma Patients: Combined Analysis of Carfilzomib Trials
Authors: Maria-Victoria Mateos, Jesus G. Berdeja, Meletios A Dimopoulos, David S Siegel, P Joy Ho, Mei Huang, Martina Sersch, Anita Zahlten-Kumeli, Amy S Kimball, Katja Weisel
Journal: Blood (2018)